Ifenprodil as a treatment for IPF approved by FDA Algernon Pharmaceuticals' (AGN.c AGNPF) filing to get Orphan Drug Designation for Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF) was recently approved by the US FDA.
The designation is mandatory for AGN to be able to commercialize its Ifenprodil treatment. So the approval means that AGN has passed a significant hurdle.
With the designation granted, AGN is planning the next steps for a clinical study of Ifenprodil for the treatment of IPF and chronic cough.
https://www.nxtlifescience.com/news-releases/cse-agn-algernon-pharmaceuticals-receives-u-s-fda-orphan-drug-designation-for-ifenprodil-for-the-treatment-of-idiopathic-pulmonary-fibrosis/#